Drug-coated balloons: Technical and clinical progress. (December 2020)

• Record Type: Journal Article
• Authors: Ang, Huiying; Koppara, Tobias R; Cassese, Salvatore; Ng, Jaryl; Joner, Michael; Foin, Nicolas
• Is Part Of: Vascular medicine. Volume 25:Number 6(2020)
• Page Start: 577
• Page End: 587
• Publication Date: 2020-12
• Subjects: coronary artery disease (CAD) -- drug-coated balloons -- percutaneous coronary interventions -- peripheral artery disease (PAD) -- peripheral interventions; Blood-vessels -- Diseases -- Periodicals; Peripheral vascular diseases -- Periodicals; Vascular Diseases -- Periodicals; Vaisseaux sanguins -- Maladies -- Périodiques; Maladies vasculaires périphériques -- Périodiques; 616.13
• DOI: 10.1177/1358863X20927791
• Languages: English
• ISSNs: 1358-863X

Abstract

The advancement of drug-coated balloons (DCB) presents an alternative nonstent method in the percutaneous treatment of atherosclerotic lesions. While the current generation of drug-eluting stents (DES) are the device of choice, especially in coronary artery disease (CAD), DCB has potential applications in the treatment of de novo lesions, in-stent restenosis (ISR), bifurcations, and in peripheral artery disease (PAD). In terms of coronary clinical experience, DCB is used most in ISR scenarios and more data are collected to support the use of DCB in de novo lesions compared to best-in-class DES. The use of DCB in bifurcation side branch treatment has demonstrated safety, and with good angiographic and clinical outcomes, but more data from randomized trials will be required to assess its clinical value. For PAD, the clinical outcomes of DCB with and without debulking devices in diseased femoropopliteal arteries and treatment of below-the-knee (BTK) vessels with DCB are discussed. Current data demonstrated conflicting long-term safety outcomes in the use of paclitaxel devices in the femoral and/or popliteal arteries, while the role of DCB in BTK disease remains uncertain due to a lack of randomized controlled trial data. In summary, this review provides an overall view of current DCB technologies and progress, followed by an update on DCB clinical data in the treatment of CAD and PAD.